Vivozon Pharma Signs Contract to Supply Finished Anafrasew Products to Hainan Medical Special Zone in China

Supplying to Boao Lecheng Medical Special Zone

"Reviewing NMPA Approval and Market Entry"

VIVOZON Pharmaceuticals announced on the 27th that it has signed a supply agreement for the finished product of its non-narcotic analgesic 'Anapraju' with Company G, located in Hainan Province, China.

VIVOZON Pharmaceuticals Company Logo Image. VIVOZON Pharmaceuticals

This agreement will be carried out with a focus on the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province. The Hainan Medical Special Zone is a medical and bio-specialized area designated by the Chinese government, where overseas-approved pharmaceuticals can be used on a limited basis separately from the official approval of the National Medical Products Administration (NMPA) of China.

VIVOZON Pharmaceuticals plans to utilize Company G’s local network and experience in regulatory affairs and distribution to supply Anapraju within the medical special zone. The company intends to collect prescription data from Chinese patients and will sequentially consider entering the mainland Chinese market and obtaining NMPA approval.

VIVOZON Pharmaceuticals is planning to sign a licensing agreement for Anapraju with its affiliate VIVOZON, specifically targeting Hainan Province. Under this structure, VIVOZON Pharmaceuticals will export the finished product while VIVOZON will receive royalty payments.

This content was produced with the assistance of AI translation services.